|
| 36922590 | Spatial mapping of mitochondrial networks and bioenergetics in lung cancer. | Nature | 2023 |
| 37599056 | Letter to Editor. Re "de Leeuw SP, et al. Analysis of Serious Weight Gain in Patients Using Alectinib for ALK Positive Lung Cancer," Semaglutide a Potential Treatment for Serious Weight Gain From ALK Tyrosine Kinase Inhibitors? | J Thorac Oncol | 2023 |
| 37599046 | Unresectable Stage III NSCLC Should Not be Treated With Neoadjuvant Therapy and Re-Evaluated for Resection. | J Thorac Oncol | 2023 |
| 37730274 | CCL21-DC in situ vaccination in murine NSCLC overcomes resistance to immunotherapy and generates systemic tumor-specific immunity. | J Immunother Cancer | 2023 |
| 37023987 | Safety and Efficacy Results From iSABR, a Phase 1 Study of Stereotactic ABlative Radiotherapy in Combination With Durvalumab for Early-Stage Medically Inoperable Non-Small Cell Lung Cancer. | Int J Radiat Oncol Biol Phys | 2023 |
| 37327461 | First-in-Human, Phase I Dose-Escalation and Dose-Expansion Study of Trophoblast Cell-Surface Antigen 2-Directed Antibody-Drug Conjugate Datopotamab Deruxtecan in Non-Small-Cell Lung Cancer: TROPION-PanTumor01. | J Clin Oncol | 2023 |
| 36923158 | Brief Report: Severe Pneumonitis After Combined Thoracic Radiotherapy and Osimertinib. | JTO Clin Res Rep | 2023 |
| 36922590 | Spatial mapping of mitochondrial networks and bioenergetics in lung cancer. | Nature | 2023 |
| 37536938 | Dysthyroidism during immune checkpoint inhibitors is associated with improved overall survival in adult cancers: data mining of 1385 electronic patient records. | J Immunother Cancer | 2023 |
| 37532930 | Consent document translation expense hinders inclusive clinical trial enrolment. | Nature | 2023 |
| 37348993 | An Unexpected Partnership: Histone Deacetylase 6 and Glutaminase Inhibition Provide an Opportunity to Overcome Resistance in KRAS and LKB1 Co-mutant Lung Tumors. | J Thorac Oncol | 2023 |
| 37730274 | CCL21-DC in situ vaccination in murine NSCLC overcomes resistance to immunotherapy and generates systemic tumor-specific immunity. | J Immunother Cancer | 2023 |
| 37536938 | Dysthyroidism during immune checkpoint inhibitors is associated with improved overall survival in adult cancers: data mining of 1385 electronic patient records. | J Immunother Cancer | 2023 |
| 37532930 | Consent document translation expense hinders inclusive clinical trial enrolment. | Nature | 2023 |
| 37599056 | Letter to Editor. Re "de Leeuw SP, et al. Analysis of Serious Weight Gain in Patients Using Alectinib for ALK Positive Lung Cancer," Semaglutide a Potential Treatment for Serious Weight Gain From ALK Tyrosine Kinase Inhibitors? | J Thorac Oncol | 2023 |
| 37599046 | Unresectable Stage III NSCLC Should Not be Treated With Neoadjuvant Therapy and Re-Evaluated for Resection. | J Thorac Oncol | 2023 |
| 37023987 | Safety and Efficacy Results From iSABR, a Phase 1 Study of Stereotactic ABlative Radiotherapy in Combination With Durvalumab for Early-Stage Medically Inoperable Non-Small Cell Lung Cancer. | Int J Radiat Oncol Biol Phys | 2023 |
| 37348993 | An Unexpected Partnership: Histone Deacetylase 6 and Glutaminase Inhibition Provide an Opportunity to Overcome Resistance in KRAS and LKB1 Co-mutant Lung Tumors. | J Thorac Oncol | 2023 |
| 37327461 | First-in-Human, Phase I Dose-Escalation and Dose-Expansion Study of Trophoblast Cell-Surface Antigen 2-Directed Antibody-Drug Conjugate Datopotamab Deruxtecan in Non-Small-Cell Lung Cancer: TROPION-PanTumor01. | J Clin Oncol | 2023 |
| 36923158 | Brief Report: Severe Pneumonitis After Combined Thoracic Radiotherapy and Osimertinib. | JTO Clin Res Rep | 2023 |
| 35031176 | What is the current role of immunotherapy in EGFR mutant advanced NSCLC? | Lung Cancer | 2022 |
| 36166003 | Mass Cytometry Reveals Classical Monocytes, NK Cells, and ICOS+ CD4+ T Cells Associated with Pembrolizumab Efficacy in Patients with Lung Cancer. | Clin Cancer Res | 2022 |
| 35031176 | What is the current role of immunotherapy in EGFR mutant advanced NSCLC? | Lung Cancer | 2022 |
| 36166003 | Mass Cytometry Reveals Classical Monocytes, NK Cells, and ICOS+ CD4+ T Cells Associated with Pembrolizumab Efficacy in Patients with Lung Cancer. | Clin Cancer Res | 2022 |
| 34000388 | Society of Interventional Radiology Quality Improvement Standards on Percutaneous Ablation of Non-Small Cell Lung Cancer and Metastatic Disease to the Lungs. | J Vasc Interv Radiol | 2021 |
| 34000388 | Society of Interventional Radiology Quality Improvement Standards on Percutaneous Ablation of Non-Small Cell Lung Cancer and Metastatic Disease to the Lungs. | J Vasc Interv Radiol | 2021 |
| 34507111 | Immune checkpoint inhibitor induced thyroid dysfunction is a frequent event post-treatment in NSCLC. | Lung Cancer | 2021 |
| 34806054 | Technical Feasibility and Safety of Repeated Computed Tomography-Guided Transthoracic Intratumoral Injection of Gene-Modified Cellular Immunotherapy in Metastatic NSCLC. | JTO Clin Res Rep | 2021 |
| 34806054 | Technical Feasibility and Safety of Repeated Computed Tomography-Guided Transthoracic Intratumoral Injection of Gene-Modified Cellular Immunotherapy in Metastatic NSCLC. | JTO Clin Res Rep | 2021 |
| 34507111 | Immune checkpoint inhibitor induced thyroid dysfunction is a frequent event post-treatment in NSCLC. | Lung Cancer | 2021 |
| 32886906 | Immune-Related Adverse Events (irAEs): Implications for Immune Checkpoint Inhibitor Therapy. | J Natl Compr Canc Netw | 2020 |
| 32886906 | Immune-Related Adverse Events (irAEs): Implications for Immune Checkpoint Inhibitor Therapy. | J Natl Compr Canc Netw | 2020 |
| 35121931 | Mutational landscape influences immunotherapy outcomes among patients with non-small-cell lung cancer with human leukocyte antigen supertype B44. | Nat Cancer | 2020 |
| 35121931 | Mutational landscape influences immunotherapy outcomes among patients with non-small-cell lung cancer with human leukocyte antigen supertype B44. | Nat Cancer | 2020 |
| 30676857 | Does Platinum-Based Chemotherapy Still Have a Role in First-Line Treatment of Advanced Non-Small-Cell Lung Cancer? | J Clin Oncol | 2019 |
| 31086949 | EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer. | Ann Oncol | 2019 |
| 30676857 | Does Platinum-Based Chemotherapy Still Have a Role in First-Line Treatment of Advanced Non-Small-Cell Lung Cancer? | J Clin Oncol | 2019 |
| 31106131 | Lack of clearly defined role for anti-programmed death-(ligand) 1 therapy in epidermal growth factor receptor mutated non-small cell lung cancer. | Transl Lung Cancer Res | 2019 |
| 31086949 | EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer. | Ann Oncol | 2019 |
| 31106131 | Lack of clearly defined role for anti-programmed death-(ligand) 1 therapy in epidermal growth factor receptor mutated non-small cell lung cancer. | Transl Lung Cancer Res | 2019 |
| 29593885 | High-profile studies frequently and repetitively present data on the same patients, particularly in immunotherapy studies. | J Thorac Dis | 2018 |
| 29874546 | A Phase II Study of Pembrolizumab in EGFR-Mutant, PD-L1+, Tyrosine Kinase Inhibitor Naïve Patients With Advanced NSCLC. | J Thorac Oncol | 2018 |
| 30056858 | The Italian Nivolumab Expanded Access Program Confirms the Limitations of Single-Agent PD-1 Inhibition in EGFR-Mutant and Never-Smoking Patients with NSCLC. | J Thorac Oncol | 2018 |
| 29382669 | Treatment-Related Adverse Events Predict Improved Clinical Outcome in NSCLC Patients on KEYNOTE-001 at a Single Center. | Cancer Immunol Res | 2018 |
| 29593885 | High-profile studies frequently and repetitively present data on the same patients, particularly in immunotherapy studies. | J Thorac Dis | 2018 |
| 29874546 | A Phase II Study of Pembrolizumab in EGFR-Mutant, PD-L1+, Tyrosine Kinase Inhibitor Naïve Patients With Advanced NSCLC. | J Thorac Oncol | 2018 |
| 30056858 | The Italian Nivolumab Expanded Access Program Confirms the Limitations of Single-Agent PD-1 Inhibition in EGFR-Mutant and Never-Smoking Patients with NSCLC. | J Thorac Oncol | 2018 |
| 29382669 | Treatment-Related Adverse Events Predict Improved Clinical Outcome in NSCLC Patients on KEYNOTE-001 at a Single Center. | Cancer Immunol Res | 2018 |
| 27925665 | Viral oncoprotein antibodies as a marker for recurrence of Merkel cell carcinoma: A prospective validation study. | Cancer | 2017 |
| 28551359 | Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial. | Lancet Oncol | 2017 |